Cellectar Biosciences (CLRB) vs Vyome (HIND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cellectar Biosciences (CLRB) has outperformed Vyome (HIND) over the past year, losing 72.1% versus a loss of 75.9%. Over five years, CLRB leads with a -99.6% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($8.4 million vs $8.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLRB | HIND |
|---|---|---|
| Share price | $0.797 | $1.20 |
| Market cap | $8.00M | $8.42M |
| 1-day change | -11.50% | -17.24% |
| YTD return | -72.98% | -65.12% |
| 1-year return | -72.13% | -75.90% |
| 5-year return | -99.63% | -100.00% |
| P/E ratio (TTM) | — | 0.25 |
| EPS (TTM) | $-2.34 | $4.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $319.71K |
| Revenue growth (YoY) | — | +24.43% |
| Net income (latest FY) | $-21.79M | $-10.26M |
| Gross margin | — | 68.43% |
| Operating margin | — | -3269.35% |
| Net margin | — | -3209.75% |
| 52-week high | $4.70 | $5.88 |
| 52-week low | $0.7596 | $1.20 |
| Distance from 52-week high | -83.04% | -79.59% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1342.91% | +635.83% |
| Average volume | 97.96K | 13.92K |
| Shares outstanding | 10.04M | 7.02M |
| Employees | 11 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cellectar Biosciences
CLRB stock →Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CLRB vs HIND FAQ
Which is bigger, Cellectar Biosciences or Vyome?
Vyome (HIND) is larger, with a market capitalization of $8.42M compared with $8.00M for Cellectar Biosciences (CLRB).
Which stock has performed better over the past year, CLRB or HIND?
CLRB returned -72.13% over the past 12 months, compared with -75.90% for HIND (price return, excluding dividends). Past performance does not predict future results.
Are Cellectar Biosciences and Vyome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.